Eintrag weiter verarbeiten
Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification.
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Journal of Clinical Oncology, 36, 2018, 6_suppl, S. 39-39 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Nguyen, Paul L. Zhang, Jingbin Yousefi, Kasra Davicioni, Elai Den, Robert Benjamin Feng, Felix Y Spratt, Daniel Eidelberg Nguyen, Paul L. Zhang, Jingbin Yousefi, Kasra Davicioni, Elai Den, Robert Benjamin Feng, Felix Y Spratt, Daniel Eidelberg |
|---|---|
| author |
Nguyen, Paul L. Zhang, Jingbin Yousefi, Kasra Davicioni, Elai Den, Robert Benjamin Feng, Felix Y Spratt, Daniel Eidelberg |
| spellingShingle |
Nguyen, Paul L. Zhang, Jingbin Yousefi, Kasra Davicioni, Elai Den, Robert Benjamin Feng, Felix Y Spratt, Daniel Eidelberg Journal of Clinical Oncology Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. Cancer Research Oncology |
| author_sort |
nguyen, paul l. |
| spelling |
Nguyen, Paul L. Zhang, Jingbin Yousefi, Kasra Davicioni, Elai Den, Robert Benjamin Feng, Felix Y Spratt, Daniel Eidelberg 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2018.36.6_suppl.39 <jats:p> 39 </jats:p><jats:p> Background: Prior studies suggested integrated clinical-genomic risk grouping can more accurately prognosticate prostate cancer (PCa) outcome than NCCN clinical risk. We evaluated the potential for genomic testing to reclassify patients in a manner that could change management compared to NCCN risk groups. Methods: We evaluated 4,474 consecutive patients with PCa who received the Decipher Biopsy test between 01/2016-08/2017 and had information to determine NCCN risk. Genomic categorizations with the potential to change management were defined as NCCN very low/low to genomic intermediate or high (active surveillance to active treatment), NCCN favorable intermediate to genomic high (radiation therapy [RT] alone to RT plus androgen deprivation therapy [ADT]), NCCN unfavorable intermediate to genomic low (RT + ADT to RT alone), NCCN high risk to genomic low (RT + long term ADT to RT + short term ADT). Results: There were 927 NCCN low-risk, 2,427 intermediate, and 1,120 high-risk patients. Among NCCN low-risk, the incidence of genomic low, intermediate, and high risk was 58.7%, 25.0%, and 16.3% respectively, for NCCN intermediate it was 36.5%, 27.6%, and 35.8%, and for NCCN high risk it was 15.9%, 17.1%, and 67.1%. Management could have been changed in the 41.3% of NCCN low risk patients with intermediate or high genomic risk, 26.7% of favorable intermediate risk patients who had high genomic risk, 32.4% of unfavorable intermediate risk patients with low genomic risk, and 15.9% of high risk patients with low genomic risk. Conclusions: A slight majority (54%) of Decipher Biopsy users have NCCN intermediate-risk disease, likely reflecting a need for further prognostic information to refine recommendations in intermediate risk. Reclassification of NCCN groups by genomic risk was common and an integrated clinical-genomic risk system could have altered treatment recommendations in 41.3% of NCCN low, 26.7% of favorable intermediate, 32.4% of unfavorable intermediate risk, and 15.9% of high risk patients. </jats:p> Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2018.36.6_suppl.39 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxOC4zNi42X3N1cHBsLjM5 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxOC4zNi42X3N1cHBsLjM5 |
| institution |
DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 |
| imprint |
American Society of Clinical Oncology (ASCO), 2018 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2018 |
| issn |
1527-7755 0732-183X |
| issn_str_mv |
1527-7755 0732-183X |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
nguyen2018prospectiveanalysisof4474prostatebiopsiestoevaluatepotentialtreatmentmanagementimpactofcombinedclinicalgenomicriskclassification |
| publishDateSort |
2018 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_unstemmed |
Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_full |
Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_fullStr |
Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_full_unstemmed |
Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_short |
Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_sort |
prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2018.36.6_suppl.39 |
| publishDate |
2018 |
| physical |
39-39 |
| description |
<jats:p> 39 </jats:p><jats:p> Background: Prior studies suggested integrated clinical-genomic risk grouping can more accurately prognosticate prostate cancer (PCa) outcome than NCCN clinical risk. We evaluated the potential for genomic testing to reclassify patients in a manner that could change management compared to NCCN risk groups. Methods: We evaluated 4,474 consecutive patients with PCa who received the Decipher Biopsy test between 01/2016-08/2017 and had information to determine NCCN risk. Genomic categorizations with the potential to change management were defined as NCCN very low/low to genomic intermediate or high (active surveillance to active treatment), NCCN favorable intermediate to genomic high (radiation therapy [RT] alone to RT plus androgen deprivation therapy [ADT]), NCCN unfavorable intermediate to genomic low (RT + ADT to RT alone), NCCN high risk to genomic low (RT + long term ADT to RT + short term ADT). Results: There were 927 NCCN low-risk, 2,427 intermediate, and 1,120 high-risk patients. Among NCCN low-risk, the incidence of genomic low, intermediate, and high risk was 58.7%, 25.0%, and 16.3% respectively, for NCCN intermediate it was 36.5%, 27.6%, and 35.8%, and for NCCN high risk it was 15.9%, 17.1%, and 67.1%. Management could have been changed in the 41.3% of NCCN low risk patients with intermediate or high genomic risk, 26.7% of favorable intermediate risk patients who had high genomic risk, 32.4% of unfavorable intermediate risk patients with low genomic risk, and 15.9% of high risk patients with low genomic risk. Conclusions: A slight majority (54%) of Decipher Biopsy users have NCCN intermediate-risk disease, likely reflecting a need for further prognostic information to refine recommendations in intermediate risk. Reclassification of NCCN groups by genomic risk was common and an integrated clinical-genomic risk system could have altered treatment recommendations in 41.3% of NCCN low, 26.7% of favorable intermediate, 32.4% of unfavorable intermediate risk, and 15.9% of high risk patients. </jats:p> |
| container_issue |
6_suppl |
| container_start_page |
39 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
36 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792328296861532161 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:51:02.432Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Prospective+analysis+of+4%2C474+prostate+biopsies+to+evaluate+potential+treatment+management+impact+of+combined+clinical-genomic+risk+classification.&rft.date=2018-02-20&genre=article&issn=1527-7755&volume=36&issue=6_suppl&spage=39&epage=39&pages=39-39&jtitle=Journal+of+Clinical+Oncology&atitle=Prospective+analysis+of+4%2C474+prostate+biopsies+to+evaluate+potential+treatment+management+impact+of+combined+clinical-genomic+risk+classification.&aulast=Spratt&aufirst=Daniel+Eidelberg&rft_id=info%3Adoi%2F10.1200%2Fjco.2018.36.6_suppl.39&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792328296861532161 |
| author | Nguyen, Paul L., Zhang, Jingbin, Yousefi, Kasra, Davicioni, Elai, Den, Robert Benjamin, Feng, Felix Y, Spratt, Daniel Eidelberg |
| author_facet | Nguyen, Paul L., Zhang, Jingbin, Yousefi, Kasra, Davicioni, Elai, Den, Robert Benjamin, Feng, Felix Y, Spratt, Daniel Eidelberg, Nguyen, Paul L., Zhang, Jingbin, Yousefi, Kasra, Davicioni, Elai, Den, Robert Benjamin, Feng, Felix Y, Spratt, Daniel Eidelberg |
| author_sort | nguyen, paul l. |
| container_issue | 6_suppl |
| container_start_page | 39 |
| container_title | Journal of Clinical Oncology |
| container_volume | 36 |
| description | <jats:p> 39 </jats:p><jats:p> Background: Prior studies suggested integrated clinical-genomic risk grouping can more accurately prognosticate prostate cancer (PCa) outcome than NCCN clinical risk. We evaluated the potential for genomic testing to reclassify patients in a manner that could change management compared to NCCN risk groups. Methods: We evaluated 4,474 consecutive patients with PCa who received the Decipher Biopsy test between 01/2016-08/2017 and had information to determine NCCN risk. Genomic categorizations with the potential to change management were defined as NCCN very low/low to genomic intermediate or high (active surveillance to active treatment), NCCN favorable intermediate to genomic high (radiation therapy [RT] alone to RT plus androgen deprivation therapy [ADT]), NCCN unfavorable intermediate to genomic low (RT + ADT to RT alone), NCCN high risk to genomic low (RT + long term ADT to RT + short term ADT). Results: There were 927 NCCN low-risk, 2,427 intermediate, and 1,120 high-risk patients. Among NCCN low-risk, the incidence of genomic low, intermediate, and high risk was 58.7%, 25.0%, and 16.3% respectively, for NCCN intermediate it was 36.5%, 27.6%, and 35.8%, and for NCCN high risk it was 15.9%, 17.1%, and 67.1%. Management could have been changed in the 41.3% of NCCN low risk patients with intermediate or high genomic risk, 26.7% of favorable intermediate risk patients who had high genomic risk, 32.4% of unfavorable intermediate risk patients with low genomic risk, and 15.9% of high risk patients with low genomic risk. Conclusions: A slight majority (54%) of Decipher Biopsy users have NCCN intermediate-risk disease, likely reflecting a need for further prognostic information to refine recommendations in intermediate risk. Reclassification of NCCN groups by genomic risk was common and an integrated clinical-genomic risk system could have altered treatment recommendations in 41.3% of NCCN low, 26.7% of favorable intermediate, 32.4% of unfavorable intermediate risk, and 15.9% of high risk patients. </jats:p> |
| doi_str_mv | 10.1200/jco.2018.36.6_suppl.39 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxOC4zNi42X3N1cHBsLjM5 |
| imprint | American Society of Clinical Oncology (ASCO), 2018 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2018 |
| institution | DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3 |
| issn | 1527-7755, 0732-183X |
| issn_str_mv | 1527-7755, 0732-183X |
| language | English |
| last_indexed | 2024-03-01T12:51:02.432Z |
| match_str | nguyen2018prospectiveanalysisof4474prostatebiopsiestoevaluatepotentialtreatmentmanagementimpactofcombinedclinicalgenomicriskclassification |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 39-39 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Nguyen, Paul L. Zhang, Jingbin Yousefi, Kasra Davicioni, Elai Den, Robert Benjamin Feng, Felix Y Spratt, Daniel Eidelberg 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2018.36.6_suppl.39 <jats:p> 39 </jats:p><jats:p> Background: Prior studies suggested integrated clinical-genomic risk grouping can more accurately prognosticate prostate cancer (PCa) outcome than NCCN clinical risk. We evaluated the potential for genomic testing to reclassify patients in a manner that could change management compared to NCCN risk groups. Methods: We evaluated 4,474 consecutive patients with PCa who received the Decipher Biopsy test between 01/2016-08/2017 and had information to determine NCCN risk. Genomic categorizations with the potential to change management were defined as NCCN very low/low to genomic intermediate or high (active surveillance to active treatment), NCCN favorable intermediate to genomic high (radiation therapy [RT] alone to RT plus androgen deprivation therapy [ADT]), NCCN unfavorable intermediate to genomic low (RT + ADT to RT alone), NCCN high risk to genomic low (RT + long term ADT to RT + short term ADT). Results: There were 927 NCCN low-risk, 2,427 intermediate, and 1,120 high-risk patients. Among NCCN low-risk, the incidence of genomic low, intermediate, and high risk was 58.7%, 25.0%, and 16.3% respectively, for NCCN intermediate it was 36.5%, 27.6%, and 35.8%, and for NCCN high risk it was 15.9%, 17.1%, and 67.1%. Management could have been changed in the 41.3% of NCCN low risk patients with intermediate or high genomic risk, 26.7% of favorable intermediate risk patients who had high genomic risk, 32.4% of unfavorable intermediate risk patients with low genomic risk, and 15.9% of high risk patients with low genomic risk. Conclusions: A slight majority (54%) of Decipher Biopsy users have NCCN intermediate-risk disease, likely reflecting a need for further prognostic information to refine recommendations in intermediate risk. Reclassification of NCCN groups by genomic risk was common and an integrated clinical-genomic risk system could have altered treatment recommendations in 41.3% of NCCN low, 26.7% of favorable intermediate, 32.4% of unfavorable intermediate risk, and 15.9% of high risk patients. </jats:p> Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. Journal of Clinical Oncology |
| spellingShingle | Nguyen, Paul L., Zhang, Jingbin, Yousefi, Kasra, Davicioni, Elai, Den, Robert Benjamin, Feng, Felix Y, Spratt, Daniel Eidelberg, Journal of Clinical Oncology, Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification., Cancer Research, Oncology |
| title | Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_full | Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_fullStr | Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_full_unstemmed | Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_short | Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_sort | prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| title_unstemmed | Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2018.36.6_suppl.39 |